NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, today announced that new, positive clinical data on its lead candidate, alpha-1 antitrypsin (“AAT”), has been presented at the annual congress of the American Thoracic Society (“ATS”), May 15 – 20, San Diego, California.
